Wall Street Zen Downgrades Tango Therapeutics (NASDAQ:TNGX) to Hold

Tango Therapeutics (NASDAQ:TNGX) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

A number of other brokerages have also recently issued reports on TNGX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tango Therapeutics in a report on Wednesday, January 21st. Wolfe Research started coverage on Tango Therapeutics in a research report on Tuesday, November 18th. They issued a “peer perform” rating for the company. HC Wainwright increased their price objective on Tango Therapeutics from $13.00 to $27.00 and gave the company a “buy” rating in a report on Friday. Mizuho began coverage on Tango Therapeutics in a report on Monday, February 23rd. They set an “outperform” rating and a $19.00 price objective on the stock. Finally, Guggenheim raised their price objective on Tango Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Friday. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $18.25.

Tango Therapeutics Stock Up 0.7%

NASDAQ TNGX opened at $16.95 on Friday. The stock has a market capitalization of $2.28 billion, a PE ratio of -19.48 and a beta of 1.76. Tango Therapeutics has a 12-month low of $1.03 and a 12-month high of $17.63. The company has a 50 day moving average price of $11.86 and a two-hundred day moving average price of $9.44.

Tango Therapeutics (NASDAQ:TNGX) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.02. Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 66.01%. As a group, equities analysts anticipate that Tango Therapeutics will post -1.19 EPS for the current year.

Insider Buying and Selling

In other Tango Therapeutics news, insider Adam Crystal sold 54,345 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $12.77, for a total transaction of $693,985.65. Following the completion of the transaction, the insider owned 132,873 shares of the company’s stock, valued at $1,696,788.21. The trade was a 29.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Barbara Weber sold 30,519 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total transaction of $374,162.94. Following the sale, the director owned 1,629,254 shares of the company’s stock, valued at $19,974,654.04. This trade represents a 1.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 113,633 shares of company stock worth $1,420,857 in the last quarter. 7.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Tango Therapeutics

Several large investors have recently made changes to their positions in the business. Adage Capital Partners GP L.L.C. boosted its stake in Tango Therapeutics by 322.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 10,607,924 shares of the company’s stock valued at $93,986,000 after purchasing an additional 8,096,924 shares during the period. Caligan Partners LP bought a new position in Tango Therapeutics in the 4th quarter worth approximately $33,047,000. Goldman Sachs Group Inc. lifted its holdings in shares of Tango Therapeutics by 227.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 4,942,414 shares of the company’s stock worth $43,790,000 after buying an additional 3,432,939 shares during the last quarter. Logos Global Management LP lifted its holdings in shares of Tango Therapeutics by 342.1% during the fourth quarter. Logos Global Management LP now owns 4,200,000 shares of the company’s stock worth $37,212,000 after buying an additional 3,250,000 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP bought a new stake in shares of Tango Therapeutics in the third quarter valued at approximately $25,924,000. Institutional investors and hedge funds own 78.99% of the company’s stock.

Tango Therapeutics News Summary

Here are the key news stories impacting Tango Therapeutics this week:

• Positive Sentiment: Clinical collaboration with Erasca to test ERAS‑0015/vopimetostat in MTAP‑deleted, RAS‑mutant cancers expands Tango’s clinical footprint and creates near‑term partnership newsflow that likely drove buying interest and record highs. TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS
• Positive Sentiment: HC Wainwright sharply raised its price target to $27 (buy), a large explicit upside that can boost sentiment and buy‑side conviction. HC Wainwright price target raise
• Positive Sentiment: Guggenheim raised its target to $20 and reiterated a buy rating, adding to analyst momentum and supporting the share‑price lift. Guggenheim price target raise
• Positive Sentiment: Wedbush raised its target to $19 with an “outperform” rating, another vote of confidence from sell‑side analysts that can attract new buyers. Wedbush price target raise
• Positive Sentiment: An investment firm added ~1.1M shares (~$9.5M), increasing its reported position materially — institutional buying that signals conviction and can underpin the rally. Investment Firm Bets Big on TNGX Stock
• Neutral Sentiment: Quarterly results beat EPS estimates by $0.02 (reported -$0.29 vs. -$0.31) — a modest positive but company remains unprofitable with negative margins and ROE, so financials are unlikely to change valuation narrative immediately. Tango Therapeutics press release
• Negative Sentiment: A Seeking Alpha piece warns against buying into the rally despite PRMT5 promise, highlighting clinical, competitive and valuation risks that could limit upside or prompt pullbacks if trial data or execution falter. Tango Therapeutics: I’m Not Buying Into Latest Rally

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.